Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

The company believes these combinations create a broader approach to treating neurodegenerative diseases ・Preclinical studies have demonstrated these combinations significant ...

In patients with type 2 diabetes, GLP-1 receptor agonists and SGLT2 inhibitors have similar kidney and cardiovascular outcomes. Similar kidney and cardiovascular outcomes are found with glucagon-like ...

Results of a recent study found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...

Terns Pharma is in the process of developing TERN-601 for the treatment of patients with obesity. See why I rate TERN stock ...

These findings expose a broad gap in screening for chronic kidney disease that is especially concerning now that there are ...

Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with ...

Annual National Conference was held Sep. 4-6 in Orlando, Florida. Managed Healthcare Executive is the official publication of ...

SGLT2 inhibitors and dulaglutide are associated with comparable risk for dementia; however, it is uncertain whether these findings generalize to newer GLP-1 RAs.